Pro Bono Bio's Themes for a Healthier World: Developing New Products : Commercialisation : Humanitarian
Developing New Products
Pro Bono Bio R&D and Manufacturing new medicines for a healthier world
Welcome to Pro Bono Bio
Pro Bono Bio was launched on 12 September 2011 in Moscow marking the visit of British Prime Minister David Cameron to encourage successful Anglo Russian technology projects and companies.
David Cameron commenting on the launch of Pro Bono Bio said “This is a great example of UK- Russia collaboration at the cutting edge of R&D. It demonstrates how British businesses can work together with their Russian counterparts to expand into new areas, creating jobs and prosperity here in the UK."
Pro Bono Bio is an international healthcare company born of such an Anglo Russian partnership, based on healthcare experience in product development, commercialisation and finance in London, international capital and the investment and support of RUSNANO in Moscow.
We are the global leader in nano-physical healthcare products and our vision is to build a new international healthcare company based on innovation in both our product development and our business model. We partner with specialist service providers to bring the best talent to bear on key unmet medical needs. In doing so we expect to create and market several commercially important new therapies and thereby grow a new valuable healthcare company.
Flexiseq Osteoarthritis pain relief
Pro Bono Bio launched its first medicine, FLEXISEQ, for the treatment of pain associated with osteoarthritis on 12 September 2011.
FLEXISEQ is the first of an attractive pipeline of products under development that are due for launch over the next five years. Its key benefits are:
- Proven pain relief and restoration of joint function
- Excellent Safety Profile.
- FLEXISEQ is a convenient topical gel
- FLEXISEQ has NO known drug interactions and has been used in conjunction with other medications prescribed for the pain of osteoarthritis
Nearly all countries report a 10+% incidence of osteoarthritis (and chronic joint pain) and roughly half of those are diagnosed; many of which are seeking improvements in their long term treatment. FLEXISEQ is now successfully launched in Germany, Austria, Ireland, Turkey, Singapore, Malaysia and the UK.
FLEXISEQ is the subject of several global patents and is a trademark beneficially owned by Pro Bono Bio.
Humanitarian
Pro Bono Bio, Humanitarian from the Get Go!
Humanitarian Ethos
You are welcome to explore our site to find out more. We particularly recommend you review our first product FLEXISEQ which features the new Sequessome Technology™.
Pro Bono Bio is a commercial organisation based on innovation and partnership, but it also has a core humanitarian value, with a commitment to ship free product to selected disadvantaged areas of the world matching the sales of products at normal prices elsewhere.
Pro Bono Bio made its first humanitarian donation to poor Hajj pilgrims from West Africa in 2012 via the Commission for Pilgrimage to Holy places of Islam.
Pro Bono Bio is working with Arthritis Research UK and LloydsPharmacy to raise a humanitarian contribution to independent medical research selected and managed by Arthritis Research UK. Our aim is to raise £500,000 during the exclusive charity period. This is a good first example of Pro Bono Bio contributing to external Medical Research.
-
FLEXISEQ Gel Launched in UK Pioneering joint pain treatment supports leading Arthritis charity
3rd December 2013, London: Pro Bono Bio®, the global leader in nano-physical healthcare products, announces the UK Charity launch of FLEXISEQ™, the innovative drug-free, safe treatment for joint pain...
-
Lancet highlights potential dangers with the most commonly prescribed pain killers
Prof Dr. Martin Wehling, director of the Institute of Experimental and Clinical Pharmacology and Toxicology, Mannheim, University of Heidelberg, said "The Lancet article clearly demonstrates what has been known for a while, that NSAIDs have significant side effects."...
-
FLEXISEQ®: Rheumatology publishes clinical evidence supporting a novel, drug-free osteoarthritis treatment
London, England 10 April 2013 –Key phase III trial data supporting Pro Bono Bio's ("PBB") drug-free osteoarthritis treatment FLEXISEQ...
-
FLEXISEQ™ – The Innovative Treatment Option for Osteoarthritis
Patients who suffer from osteoarthritis, a painful and chronic joint disease, have only limited treatment options. Apart from a change in lifestyle including weight reduction and controlled physical activity, the main treatment lies in the use of non-steroidal anti-inflammatory drugs (NSAIDs). These are, however, not effective for everyone, or, because of their possible...
-
Clinically Proven Osteoarthritis "Wondergel" Launches in Singapore
Adjunct Assistant Professor Sathappan, Senior Consultant, Department of Orthopaedic Surgery, Tan Tock Seng Hospital, has used topical gel as means of treating osteoarthritis. He said, "Early to moderate osteoarthritis can be well managed with topical gel. They can facilitate optimal outcome with physiotherapy and allow in functional rehabilitation...
-
FLEXISEQ: Osteoarthritis Patient Survey Validates Clinical Success
In March 2013 Feierabend, the German product testing community, published an independent patient survey on Flexiseq. The press release and summary report can be found on the www.flexiseq.com website.
-
FLEXISEQ® Wins BVDA Innovation of 2013 Award
The BVDA president, and pharmacist Thomas Hieble, explained; “The jury awarded the prize to FLEXISEQ® in recognition of the application of its innovative Sequessome Technology® to deliver symptom relief to sufferers...
-
FLEXISEQ™ for Hajj Pilgrims
The donation was made by Pro Bono Bio's envoy Andrei Garbuz (pictured) to the head of commission for pilgrimage to holy places of Islam, Mr El Hadji Mansour DIOP in Dakar. The Commissioner General...
-
Malaysian Approval Of FLEXISEQ™ And Distribution Agreement
Pro Bono Bio is also pleased to announce that they have signed an agreement to distribute FLEXISEQ in Malaysia and the product will be available via local distribution company, Farmasia Sdn. Bhd. from early July 2012. Its first introduction to the local market is at the...
